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This Special Issue of the Journal of Risk Research was initiated to increase the 
evidence base supporting critical understanding of the use and impacts of 
transparency as a policy tool in risk management and regulation in Europe and North 
America. The lead research articles and perspectives were initially presented at a two-
day workshop supported by the Journal of Risk Research and its publisher Taylor and 
Francis, which took place in Lavandou, Provence, 19th - 20th June 2014. In this editorial 
we introduce the motivations for the special issue and offer a brief summary of the 
contribution of each article highlighting key intersections and points of concurrence. 
 
In recent years, many policymakers have received strong demands to enhance 
transparency, which has been accompanied by growing academic interest in the 
changing nature of risk communication and regulation in the EU, US and elsewhere 
(Lofstedt et. al. 2011). In particular, several scholars have begun to challenge 
assumptions that transparency is a positive good that can, for instance, promote 
accountability, enhance legitimacy and (re)build public trust. They have illuminated the 
need to examine the concept more carefully particularly highlighting that initiatives are 
not problem free while recognizing different types or varieties of transparency (e.g. 
fishbowl versus reasoned transparency or general versus particularised) (Heald, 2006; 
Hood, 2007; Lofstedt and Bouder, 2013).  
 
However, to date there has been relatively little work that has provided empirical 
evidence to inform the transparency debate and move beyond first principles (Etzioni, 
2010; Lofstedt, 2013). This has led to a dearth of research that can inform decision-
making in many policy domains. Addressing this gap, the articles in this special issue 
provide evidence on a range of issue areas, with several contributions offering a 
transatlantic comparative perspective, from which to move the transparency debate 
forwards. These contributions collectively extend academic and policy insights into the 
difficulties surrounding the policy uses, mechanisms and impacts of transparency, and 
set a path towards future avenues of inquiry and policy practice. Here we provide a 
brief summary of these contributions. 
 
The article by Lofstedt and Way sets out the context of the growing trend towards 
more open, inclusive and transparent models of regulatory decision making in recent 
years. The article also reports findings from a survey conducted to inquire into how 
members of the public are likely to react to so called ‘fish-bowl’ transparency policies 
associated with pharmaceuticals. The findings show that respondents become more 
worried and concerned, and in light of such information expressed they would seek 
more advice and consider changing their behaviour, which may be ill-advised in 
certain cases.  
 
Commentaries by Meijer, the Irish Medicines Board, Miller, Mossman, and 
Breckenridge further reflect upon and elucidate the issues raised by Lofstedt and 
Way’s article from a variety of academic, legal, regulatory and political perspectives. 
These commentaries address the presumption of an informed, confident public and 
that public trust necessarily arises from enacting transparency policies. They also 
raise practical considerations of how transparency supports the role and 
contributions of end users, such as patients, and how such information is weighed in 
the context of benefits and risks of taking drugs for them personally. The response to 
comments by Lofstedt and Way both welcomes these critical and constructive 
insights and provides a postscript to the original study concerning the growing pace 
of pharmaceutical transparency and its impacts on public/patient trust of regulators 
and companies in the sector.  
 
Taking a comparative perspective O’Connor next outlines the pressing need for 
different types of empirical studies to benefit regulatory process in the US and EU. 
O’Connor calls particular attention to addressing open questions concerning whether 
transparency improves the quality of regulations, how transparency is used in 
practice and its impacts at different levels, and who benefits from available 
transparency mechanisms. Answering this call, the articles which follow help to shed 
some further light on these issues. 
 
Adopting a comparative line of inquiry, Dudley and Wegrich examine the issue of 
regulatory reform and the relation of transparency procedures in the US and the EU 
to impact analysis and public comment. Their study makes an important contribution 
to current understandings by addressing the role of transparency in improving the 
quality of regulations, summarising different approaches within the US and EU, and 
assessing their relative merits.  
 
The article by Dixon, McCommas, Besley and Steinhardt presents an experimental 
study on the impact of transparency practices on consumer views about the labelling 
of GM foods in the US. This follows debate about the disclosure not only of product 
ingredients, but also access to the process that makes decisions about labelling. The 
study findings underscore the importance of procedural justice perceptions and their 
impact on support for controversial risk-related decisions. 
 
Also addressing the impacts of transparency policies from the perspectives of end 
users two final studies are directed towards the case of the European Medicines 
Agency transparency. In this case the release of information has aimed to enable the 
re-use of data and empower patients directly and indirectly to make more informed 
decisions. In the first study Lofstedt, Way, Bouder and Evensen find that general 
practitioners (GPs) and medical specialists have little awareness and knowledge of 
how the safety of medicines is assessed, or the procedures by which it is regulated 
and disclosed. The study respondents also felt that it was a bad idea to release 
information into the public domain before safety issues have been investigated by 
regulators. In the second study Way, Bouder, Lofstedt and Evensen examine the 
views of patients directly. Their findings show that essential information about the net 
effects of transparency policies will be missed if the perspectives of patients are not 
accounted for.  
 
In conclusion, it transpires that transparency policies alone are insufficient to address 
the real world complexities of communicating with patients and other end users. 
Much more needs to be done in this area not only to match transparency initiatives 
with science-based benefit/risk communication, but also to meet the demands of 
communicating effectively in different political and sociocultural contexts (Kasperson 
2014; Wardman 2014). 
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